Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul;35(26):1712-8.
doi: 10.1093/eurheartj/eht464. Epub 2013 Dec 2.

Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial

Ruth Peters  1 , Nigel Beckett  2 , Terry McCormack  3 , Robert Fagard  4 , Astrid Fletcher  5 , Christopher Bulpitt  6
Affiliations
Review

Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial

Ruth Peters et al. Eur Heart J. 2014 Jul.

Abstract

Although the number of individuals reaching 80 who are considered to be healthy is increasing, the very elderly are likely to have long-term conditions, to report symptoms and/or be taking at least one regular medication. The impact of antihypertensive treatment has to be taken into account in this context. The treatment regimen in Hypertension in the Very Elderly Trial with a goal blood pressure of <150/80 mmHg has been shown to provide benefits in terms of a reduction in risk of total mortality, stroke, and cardiovascular events with potential benefits and no evidence of increased risk for fracture, dementia, depression, and quality-of-life outcomes. Questions remain as to the level of benefit that would be accrued in the frailer elderly and those at extreme age, for example, over 90.

Keywords: Aged; Antihypertensives; Benefit; Elderly; Hypertension; Risk.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Forest plot of results for total mortality outcomes from the HYVET alongside trials from the 1999 meta-analysis. Relative risk with 95% confidence limits.
See this image and copyright information in PMC

References

    1. Lanzieri G. The greying of the baby boomers, a century-long view of ageing in European populations. Eurostat Statistics in focus 23/2011 http://ec.europa.eu/digital-agenda/futurium/sites/futurium/files/futuriu... . (01 November 2013)
    1. Gueyffier F, Bulpitt C, Boissel J-P, Schron E, Ekbom T, Fagard R, Casiglia E, Kerlikowske K, Coope J for the INDANA Group. Antihypertensive drugs in very old people: a sub-group meta-analysis of randomised controlled trials. Lancet. 1999;353:793–796. doi: 10.1016/S0140-6736(98)08127-6. - DOI - PubMed
    1. United Nations. World Population Ageing 1950–2050 http://www.un.org/esa/population/publications/worldageing19502050/ (26 May 2012)
    1. Amery A, Birkenhäger WH, Brixko P, Bulpitt C, Clement D, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, Forette F. Mortality and morbidity results from the European Working Party on High blood pressure in the Elderly trial. Lancet. 1985;I:1349–1354. doi: 10.1016/S0140-6736(85)91783-0. - DOI - PubMed
    1. Dahlöf B, Hansson L, Lindholm L, Scherstén B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet. 1991;338:1281–1285. doi: 10.1016/0140-6736(91)92589-T. - DOI - PubMed

Publication types

Substances